Taikang: CKBA cream, a subsidiary of the holding company, has been approved for clinical trials of children's vitiligo treatment.

Taencon announcement, a holding subsidiary Jiangsu Bochuangyuan Biopharmaceutical Technology Co., Ltd. received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial application of the safety, tolerance, efficacy, and pharmacokinetic characteristics of CKBA cream combined with narrow-band ultraviolet in children aged 2-12 with non-segmental vitiligo.